(Q44532986)

3 December 2017

0 references

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. (English)

1 reference

3 December 2017

0 references

2

1 reference

3 December 2017

A Ward

1

1 reference

3 December 2017

D Getsios

3

1 reference

3 December 2017

K Ishak

4

1 reference

3 December 2017

J O'Brien

5

1 reference

3 December 2017

R Bullock

6

1 reference

3 December 2017

AHEAD Study Group

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

International Journal of Geriatric Psychiatry

3 December 2017

published in

1 reference

3 December 2017

volume

18

1 reference

3 December 2017

issue

8

1 reference

3 December 2017

page(s)

740-747

1 reference

Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.

3 December 2017

cites work

1 reference

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

21 January 2018

1 reference

Time to nursing home admission for persons with Alzheimer's disease: the effect of health care system characteristics

21 January 2018

1 reference

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

21 January 2018

1 reference

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach

21 January 2018

1 reference

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

21 January 2018

1 reference

7 January 2021

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

1 reference

7 January 2021

1 reference

7 January 2021

Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden

1 reference

7 January 2021

Cognitive disability and direct care costs for elderly people.

1 reference

7 January 2021

Costs and cognitive disability: modelling the underlying associations.

1 reference

7 January 2021

Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS).

1 reference

7 January 2021

Residential and nursing home care of elderly people with cognitive impairment: prevalence, mortality and costs.

1 reference

7 January 2021

Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers

1 reference

7 January 2021

Nursing Homes in 10 Nations: A Comparison Between Countries and Settings

1 reference

7 January 2021

The economic burden of Alzheimer's disease care

1 reference

7 January 2021

The impact of symptom severity on the cost of Alzheimer's disease.

1 reference

7 January 2021

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

7 January 2021

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

1 reference

7 January 2021

Predicting time to nursing home care and death in individuals with Alzheimer disease.

1 reference

7 January 2021

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

1 reference

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

7 January 2021

Hallucinations, delusions, and cognitive decline in Alzheimer's disease

1 reference

7 January 2021

Estimating the relationship between disease progression and cost of care in dementia

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.919

1 reference

3 December 2017

1 reference